PE20110684A1 - Agonistas de los receptores de la melanocortina - Google Patents
Agonistas de los receptores de la melanocortinaInfo
- Publication number
- PE20110684A1 PE20110684A1 PE2011000970A PE2011000970A PE20110684A1 PE 20110684 A1 PE20110684 A1 PE 20110684A1 PE 2011000970 A PE2011000970 A PE 2011000970A PE 2011000970 A PE2011000970 A PE 2011000970A PE 20110684 A1 PE20110684 A1 PE 20110684A1
- Authority
- PE
- Peru
- Prior art keywords
- pyrrolidin
- carbonyl
- cycloalkyl
- tert
- halogen
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- -1 AMINO Chemical group 0.000 abstract 5
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- GEAXLHPORCRESC-UHFFFAOYSA-N chlorocyclohexatriene Chemical class ClC1=CC=C=C[CH]1 GEAXLHPORCRESC-UHFFFAOYSA-N 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE PIRROLIDINA DE FORMULA (1) DONDE R1 ES H, ALQUILO(C1-C10), CICLOALQUILO(C3-C7), ARILO(C6-C10), ENTRE OTROS; R2 ES FENILO O HETEROARILO DE SEIS MIEMBROS OPCIONALMENTE SUSTITUIDO CON HALOGENO, HIDROXI, CN, ENTRE OTROS; R3 ES H, ALQUILO(C1-C6) O CICLOALQUILO(C3-C7) OPCIONALMENTE SUSTITUIDO CON HALOGENO, METILO, AMINO, ENTRE OTROS; R4 ES CICLOALQUILO(C4-C7), FENILO, HETEROARILO DE SEIS MIEMBROS, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON HALOGENO, HIDROXI, ENTRE OTROS; R5 ES ALQUILO(C1-C6), DIFLUOROMETILO, CICLOALQUILO(C3-C8), AMINO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-{(3S,5S)-1-{[(3S,4R)-1-TERT-BUTIL-4-(4-CLOROFENIL)-PIRROLIDIN-3-IL]CARBONIL}-5-[(4-METILPIPERAZIN-1-IL)CARBONIL]PIRROLIDIN-3-IL}-N-(4,4-DIMETILCICLOHEXIL)-ACETAMIDA; N-[(3S,5S)-1-{[(3S,4R)-1-TERT-BUTIL-4-(2,4-DIFLUOROFENIL)PIRROLIDIN-3-IL]CARBONIL}-5-(PIPERAZIN-1-ILCARBONIL)-PIRROLIDIN-3-IL]-N-(4,4-DIMETILCICLOHEXIL)ACETAMIDA; (2S)-N-{(3S,5S)-1-{[(3S,4R)-1-TERT-BUTIL-4-(4-CLOROFENIL)PIRROLIDIN-3-IL]CARBONIL}-5-[(4-METILPIPERAZIN-1-IL)CARBONIL]PIRROLIDIN-3-IL}-N-(4,4-DIMETILCICLOHEXIL)-TETRAHIDROFURAN-2-CARBOXAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR DE LA MELANOCORTINA SIENDO UTILES EN EL TRATAMIENTO DE LA OBESIDAD, DIABETES, INFLAMACION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20080112403 | 2008-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110684A1 true PE20110684A1 (es) | 2011-09-28 |
Family
ID=42165801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011000970A PE20110684A1 (es) | 2008-11-12 | 2009-11-10 | Agonistas de los receptores de la melanocortina |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US8039622B2 (es) |
| EP (1) | EP2350060B1 (es) |
| JP (1) | JP5399506B2 (es) |
| KR (1) | KR101141976B1 (es) |
| CN (1) | CN102282141B (es) |
| AR (1) | AR074109A1 (es) |
| AU (1) | AU2009314827B2 (es) |
| BR (1) | BRPI0921063B8 (es) |
| CA (1) | CA2742248C (es) |
| CL (1) | CL2011001073A1 (es) |
| CO (1) | CO6362006A2 (es) |
| CR (1) | CR20110250A (es) |
| EA (1) | EA019146B1 (es) |
| EC (1) | ECSP11011026A (es) |
| GE (1) | GEP20135850B (es) |
| IL (1) | IL212468A0 (es) |
| MA (1) | MA32774B1 (es) |
| MX (1) | MX2011004583A (es) |
| NZ (1) | NZ592512A (es) |
| PE (1) | PE20110684A1 (es) |
| TN (1) | TN2011000222A1 (es) |
| TW (1) | TWI389903B (es) |
| UA (1) | UA99555C2 (es) |
| UY (1) | UY32238A (es) |
| WO (1) | WO2010056022A2 (es) |
| ZA (1) | ZA201103154B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA99555C2 (en) * | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| CA2825098C (en) | 2011-01-27 | 2020-03-10 | Universite De Montreal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| LT3539551T (lt) | 2011-12-29 | 2022-01-10 | Rhythm Pharmaceuticals, Inc. | Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose |
| MX2014011419A (es) | 2012-04-25 | 2014-11-25 | Hoffmann La Roche | Clorhidrato de (3,4-dicloro-fenil)-((s)-3-propil-pirrolidin-3-il)- metanona y procesos de manufacturacion. |
| CN103420981A (zh) * | 2012-05-21 | 2013-12-04 | 中国医学科学院药物研究所 | 含有取代吡咯烷基的硫代吗啉类化合物 |
| MA43038A (fr) | 2015-09-30 | 2018-08-08 | Rhythm Pharmaceuticals Inc | Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4 |
| AU2019249255A1 (en) | 2018-04-06 | 2020-11-05 | Alastair GARFIELD | Compositions for treating kidney disease |
| PE20220766A1 (es) * | 2019-11-07 | 2022-05-16 | Lg Chemical Ltd | Agonistas de receptor de melanocortina-4 |
| US20230399321A1 (en) * | 2020-10-29 | 2023-12-14 | Lg Chem, Ltd. | Crystalline form ii of melanocortin receptor agonist compound and preparation method therefor |
| CA3195328A1 (en) | 2020-10-29 | 2022-05-05 | Jin Ok HAM | Crystalline form iv of melanocortin receptor agonist compound and preparation method therefor |
| AU2021370072B2 (en) | 2020-10-29 | 2024-02-08 | Lg Chem, Ltd. | Crystalline form iii of melanocortin receptor agonist compound and method for preparing same |
| US20230373984A1 (en) | 2020-10-29 | 2023-11-23 | Lg Chem, Ltd. | Crystalline form i of melanocortin receptor agonist compound and preparation method therefor |
| MX2023004654A (es) * | 2020-10-29 | 2023-05-18 | Lg Chemical Ltd | Agonista de receptor de melanocortina-4 amorfo. |
| US20240043407A1 (en) | 2020-12-22 | 2024-02-08 | Lg Chem, Ltd. | Crystalline form i of melanocortin receptor agonist compound and method for preparing same |
| EP4249482A4 (en) | 2020-12-22 | 2024-05-15 | Lg Chem, Ltd. | Amorphous melanocortin receptor agonist and method for preparing same |
| WO2022139406A1 (ko) * | 2020-12-22 | 2022-06-30 | 주식회사 엘지화학 | 멜라노코르틴-4 수용체의 선택적 항진제로서의 용도 |
| CN116648249A (zh) * | 2020-12-22 | 2023-08-25 | 株式会社Lg化学 | 黑皮质素受体激动剂化合物的结晶形式ii及其制备方法 |
| US20240051919A1 (en) * | 2020-12-22 | 2024-02-15 | Lg Chem, Ltd. | Crystalline form iii of melanocortin receptor agonist compound and preparation method therefor |
| CN116761611A (zh) * | 2021-01-21 | 2023-09-15 | 株式会社Lg化学 | 黑皮质素-4受体激动剂的用途 |
| WO2022182194A1 (ko) | 2021-02-26 | 2022-09-01 | 주식회사 엘지화학 | 멜라노코르틴-4 수용체 작용제 |
| EP4317150A4 (en) * | 2021-05-06 | 2024-10-30 | Lg Chem, Ltd. | CRYSTAL FORM VII OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR THE PREPARATION THEREOF |
| CA3217168A1 (en) | 2021-05-06 | 2022-11-10 | Lg Chem, Ltd. | Crystalline form v of melanocortin receptor agonist compound, and method for preparing same |
| CA3217468A1 (en) * | 2021-05-07 | 2022-11-10 | Lg Chem, Ltd. | Crystal form iv of organic acid salts of melanocortin receptor agonist compound, and preparation method thereof |
| CN117242063A (zh) * | 2021-05-07 | 2023-12-15 | 株式会社Lg化学 | 黑皮质素受体激动剂化合物与香兰素的共晶及其制备方法 |
| US20240239782A1 (en) * | 2021-05-07 | 2024-07-18 | Lg Chem, Ltd. | Sulfate crystals of melanocortin receptor agonist compound and method of producing same |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534503B1 (en) | 1998-04-28 | 2003-03-18 | Lion Bioscience Ag | Melanocortin receptor-3 ligands to treat sexual dysfunction |
| JP2003505435A (ja) | 1999-06-04 | 2003-02-12 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体ゴニストとしての置換ピペリジン |
| GB0002059D0 (en) | 2000-01-28 | 2000-03-22 | Melacure Therapeutics Ab | Novel aromatic amines |
| CA2403631A1 (en) | 2000-03-23 | 2001-09-27 | Brenda L. Palucki | Spiropiperidine derivatives as melanocortin receptor agonists |
| EP1268449A4 (en) | 2000-03-23 | 2004-09-15 | Merck & Co Inc | SUBSTITUTED PIPERIDINE AS MELANOCORTIN RECEPTOR AGONISTS |
| GB0019359D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
| EP1320366A4 (en) * | 2000-08-23 | 2005-04-06 | Merck & Co Inc | SUBSTITUTED PIPERIDINES AS MELANOCORTIN RECEPTOR AGONISTS |
| DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
| EP1370558B1 (en) | 2001-01-23 | 2005-08-24 | Eli Lilly And Company | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| JP2004524297A (ja) | 2001-01-23 | 2004-08-12 | イーライ・リリー・アンド・カンパニー | メラノコルチン受容体アゴニスト |
| JP2004521117A (ja) | 2001-01-23 | 2004-07-15 | イーライ・リリー・アンド・カンパニー | メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン |
| JP4323169B2 (ja) | 2001-02-28 | 2009-09-02 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体作働薬としてのアシル化ピペリジン誘導体 |
| JP4104983B2 (ja) | 2001-02-28 | 2008-06-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体 |
| ATE430565T1 (de) | 2001-02-28 | 2009-05-15 | Merck & Co Inc | Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten |
| US6716840B2 (en) | 2001-04-09 | 2004-04-06 | Chiron Corporation | Guanidino compounds |
| US6911447B2 (en) | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
| US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| AR043434A1 (es) | 2003-03-03 | 2005-07-27 | Merck & Co Inc | Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos |
| ATE474577T1 (de) | 2003-03-26 | 2010-08-15 | Merck Sharp & Dohme | Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten |
| WO2005040109A1 (en) | 2003-10-22 | 2005-05-06 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| JP4795965B2 (ja) * | 2003-11-12 | 2011-10-19 | エルジー・ライフ・サイエンシーズ・リミテッド | メラノコルチン受容体のアゴニスト |
| GB0402492D0 (en) | 2004-02-04 | 2004-03-10 | Pfizer Ltd | Pharmaceutically active compounds |
| EP1773347A4 (en) | 2004-07-16 | 2007-09-05 | Merck & Co Inc | ACYLATED PIPERIDINE DERIVATIVES THAN MELANOCORTIN-4-RECEPTOR AGONISTS |
| CA2574156A1 (en) | 2004-07-19 | 2006-02-23 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| DE102005000666B3 (de) | 2005-01-04 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP2009503048A (ja) | 2005-08-01 | 2009-01-29 | ファイザー・リミテッド | 尿路機能障害を治療するためのｍｃ４ｒ作動薬 |
| CA2617654A1 (en) | 2005-08-04 | 2007-02-08 | Pfizer Limited | Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
| CN101277960A (zh) | 2005-09-29 | 2008-10-01 | 默克公司 | 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物 |
| JP2009510069A (ja) | 2005-09-30 | 2009-03-12 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体作働薬としてのアシル化ピペリジン誘導体 |
| JP2009511631A (ja) | 2005-10-18 | 2009-03-19 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体 |
| JP2007131570A (ja) | 2005-11-09 | 2007-05-31 | Mitsubishi Pharma Corp | 新規なアミノピロリジン誘導体 |
| WO2007096186A1 (en) | 2006-02-23 | 2007-08-30 | Santhera Pharmaceuticals (Schweiz) Ag | Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators |
| US8138188B2 (en) | 2006-02-23 | 2012-03-20 | Pfizer Inc. | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
| SI2348016T1 (sl) | 2006-06-09 | 2016-10-28 | Synact Pharma Aps | Derivati fenil pirol aminogvanidina |
| TWI332501B (en) * | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| JP2010512304A (ja) | 2006-09-27 | 2010-04-22 | メルク・シャープ・エンド・ドーム・コーポレイション | メラノコルチン−４受容体モジュレータとしてのアシル化ピペリジン誘導体 |
| UA99555C2 (en) * | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
-
2009
- 2009-10-11 UA UAA201105960A patent/UA99555C2/ru unknown
- 2009-11-03 TW TW098137194A patent/TWI389903B/zh not_active IP Right Cessation
- 2009-11-10 CA CA2742248A patent/CA2742248C/en active Active
- 2009-11-10 KR KR1020090108283A patent/KR101141976B1/ko active Active
- 2009-11-10 US US12/615,407 patent/US8039622B2/en active Active
- 2009-11-10 EP EP09826254.6A patent/EP2350060B1/en active Active
- 2009-11-10 GE GEAP2009012222 patent/GEP20135850B/en unknown
- 2009-11-10 BR BRPI0921063A patent/BRPI0921063B8/pt active IP Right Grant
- 2009-11-10 AU AU2009314827A patent/AU2009314827B2/en active Active
- 2009-11-10 US US13/128,725 patent/US8288386B2/en active Active
- 2009-11-10 CN CN200980144988.6A patent/CN102282141B/zh active Active
- 2009-11-10 PE PE2011000970A patent/PE20110684A1/es not_active Application Discontinuation
- 2009-11-10 EA EA201170676A patent/EA019146B1/ru unknown
- 2009-11-10 NZ NZ592512A patent/NZ592512A/xx not_active IP Right Cessation
- 2009-11-10 WO PCT/KR2009/006568 patent/WO2010056022A2/en not_active Ceased
- 2009-11-10 JP JP2011536237A patent/JP5399506B2/ja active Active
- 2009-11-10 MX MX2011004583A patent/MX2011004583A/es active IP Right Grant
- 2009-11-11 AR ARP090104355A patent/AR074109A1/es active IP Right Grant
- 2009-11-11 UY UY0001032238A patent/UY32238A/es not_active Application Discontinuation
-
2011
- 2011-04-26 IL IL212468A patent/IL212468A0/en unknown
- 2011-04-29 ZA ZA2011/03154A patent/ZA201103154B/en unknown
- 2011-05-03 EC EC2011011026A patent/ECSP11011026A/es unknown
- 2011-05-05 MA MA33818A patent/MA32774B1/fr unknown
- 2011-05-06 TN TN2011000222A patent/TN2011000222A1/fr unknown
- 2011-05-11 CO CO11057597A patent/CO6362006A2/es not_active Application Discontinuation
- 2011-05-12 CL CL2011001073A patent/CL2011001073A1/es unknown
- 2011-05-12 CR CR20110250A patent/CR20110250A/es unknown
- 2011-06-13 US US13/158,734 patent/US8236955B2/en active Active
- 2011-06-13 US US13/158,920 patent/US8183243B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110684A1 (es) | Agonistas de los receptores de la melanocortina | |
| PE20091974A1 (es) | Derivados de indazoles sustituidos con fenil o piridinilo | |
| PE20080830A1 (es) | Compuestos derivados de sulfonilo que modulan el receptor cb2 | |
| PE20121058A1 (es) | Compuestos que modulan el receptor de androgenos | |
| PE20081659A1 (es) | Agonistas de gpcr | |
| PE20071152A1 (es) | Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3 | |
| PE20090237A1 (es) | Derivados de sulfonamidas como inhibidores de los canales de sodio | |
| PE20110237A1 (es) | Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1) | |
| PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| PE20110367A1 (es) | DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2 | |
| RU2015119640A (ru) | Соединения n-замещенного индазол-сульфонамида с избирательной активностью в потенциал-зависимых натриевых каналах | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| PE20141375A1 (es) | Activadores de glucoquinasa | |
| PE20141228A1 (es) | Derivados de pirrolopirimidina y purina | |
| PE20080677A1 (es) | Inhibidores de pirrolotriazina cinaza | |
| PE20061366A1 (es) | Compuestos y composiciones como inhibidores de quinasa de proteina | |
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| PE20090157A1 (es) | Derivados de pirimidinona como moduladores del receptor acoplado a proteina g 119 (gpr119) | |
| PE20090240A1 (es) | Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones | |
| PE20091201A1 (es) | AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk) | |
| PE20121314A1 (es) | Derivados de 4-aminociclohexano sustituido | |
| PE20110341A1 (es) | COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA | |
| PE20061377A1 (es) | Compuestos heterociclicos fusionados | |
| PE20090592A1 (es) | Nuevos derivados de piperazina-amida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |